Beam Therapeutics

Beam Therapeutics company information, Employees & Contact Information

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Looking for a particular Beam Therapeutics employee's phone or email?

Beam Therapeutics Questions

News

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference GlobeNewswire

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - GlobeNewswire

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences GlobeNewswire

Gene Editing Pioneer Beam Therapeutics Set for Triple Conference Appearances in September 2025 - Stock Titan

Gene Editing Pioneer Beam Therapeutics Set for Triple Conference Appearances in September 2025 Stock Titan

Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire

Beam Therapeutics Presents Additional Data for BEAM-302 in GlobeNewswire

Beam Therapeutics Secures $500M Financing for Clinical Programs - Stock Titan

Beam Therapeutics Secures $500M Financing for Clinical Programs Stock Titan

The Beginning of Base Editing: An Interview with Alexis C. Komor and Nicole M. Gaudelli | The CRISPR Journal - Mary Ann Liebert, Inc.

The Beginning of Base Editing: An Interview with Alexis C. Komor and Nicole M. Gaudelli | The CRISPR Journal Mary Ann Liebert, Inc.

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in the - GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in the GlobeNewswire

Top Beam Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant